CMPXbenzinga

Piper Sandler Initiates Coverage On Compass Therapeutics with Overweight Rating, Announces Price Target of $12

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on February 19, 2025 by benzinga

    Piper Sandler Initiates Coverage On Compass Therapeutics with Overweight Rating, Announces Price Target of $12 | CMPX Stock News | Candlesense